Browse Studies — Arctuva

Phase 1

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris

A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific …

Pemphigus Vulgaris

Estimated

~$10 – $7,500

Cabaletta BioNCT04422912

Prevalence and Clinical Severity of Autoimmune Blistering Diseases

Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trial…

Pemphigus VulgarisPemphigus FoliaceusBullous Pemphigoid

Estimated

~$10 – $750

University of PennsylvaniaNCT02753777

Phase 1

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is currently …

Rheumatoid ArthritisPemphigus VulgarisGranulomatosis With Polyangiitis+1 more

Estimated

~$10 – $8,750

IRIS Research and Development, LLCNCT06581562

A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical resear…

Age-Related Macular DegenerationAllergiesAlpha-Gal Syndrome+44 more

Estimated

~$10 – $1,050

Sanguine BiosciencesNCT05635266